Q-omics provides the consensus-scored RNF187 profile across patient tissues and cancer cell-line models. RNF187 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RNF187 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, RNF187 RNA expression shows 18,434 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where RNF187 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF187 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF187 survival associations across molecular data types. RNF187 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF187 RNA expression–survival associations across cancer types. High RNF187 expression shows unfavorable associations in KICH, ACC, LIHC, BLCA and PAAD, but favorable associations in LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for RNF187 RNA expression.
This table summarizes RNF187 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RNF187. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF187 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, LUSC and KIRP. The KIRC box plot shows higher RNF187 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with RNF187 in patient tissues and cancer cell lines. In patient samples, RNF187 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF187 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
